Bronnen:
- Wang YL, Fletcher R, Yu J, Zhang L. Immunogenic effects on chemotherapy-induced tumor cell death. Genes Dis. 2018;5:194-203.,Showalter A, Limaye A, Oyer JL, et al. Cytokines in immunogenic cell death: Application for cancer immunotherapy. Cytokine. 2017;97:123-32.,Obeid M, Tesnière A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13:54-61.,Willingham SB, Volkmer JP, Gentles AJ, et al. The CD47-signal regulating protein α (SIRPα) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA. 2012;109:6662-8.,Horton TM, Gannavarapu A, Blaney PM, D’Argenio DZ, Plon SE, Berg SL. Bortezomib interations with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol. 2006;58:13-23.,Tesnière A, Schlemmer F, Boige V, et al. Immunogenic cell death of colon cancer cells treated with oxaliplatin. Oncogene. 2010;29:482-91.,Inoue S, Setoyama Y, Odaka A. Doxorubicin treatment induces tumor cell death followed by immunomodulation in a murine neuroblastoma model. Exp Ther Med. 2014;7:703-8,Fucikova J, Kralikova P, Fialova A. Human tumor cell killed by anthracyclines induce a tumor-specific immune response. Cancer Res. 2011;71:4821-33.,Zhao X, Yang K, Zhao R, et al. Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy. Biomaterials 2016; 102: 187-97.,Dudek-Perić AH, Ferreira GB, Michowicz A, et al. Antitumor immunity triggered by melphalan is potentiated by melanoma cell surface-associated calreticulin. Cancer Res. 2015;75:1603-14.,Peng RQ, Chen YB, Ding Y, et al. Expression of calreticulin is associated with infiltration of T cells in stage IIIB colon cancer. World J Gastroenterol. 2010;16:2428-34.,Spicek R, Choralambous A, Mazumder A, Vesole DH, Jagannath S, Dhodapkar MV. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity of human melanoma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood. 2007;109:4839-45.,Emile JF, Julié C, Le Malicot K, et al. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. Eur J Cancer. 2017;82:16-24.,Wemeau M, Kepp O, Tesnière A, et al. Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia. Cell Death Dis. 2010;1:e104.